expression (z-scores) of BACH1 and ETC gene expression for each patient with breast cancer (TCGA provisionaldataset, n = 1105). ATP5G2 and ATP5L also known as ATP5MC2 and ATP5MG, respectively. f, Heat map showing KEGG pathways that are negatively correlated with BACH1 levels across major...
Triple-Negative Breast Cancer Some breast cancers -- between 10% and 20% -- are known as “triple negative” because they don’t have estrogen and progesterone receptors and don’t overexpress the HER2 protein. Many breast cancers associated with the gene BRCA1 are triple negative. They are ...
Triple-negative breast cancer is more aggressive than other forms. It’s more likely to have spread beyond your breast at the time it’s found, and there’s a higher chance it will come back within the first 3 years after treatment. It’s also more likely to be fatal within the first...
Triple negative breast cancer (TNBC), which accounts for 15–20% of incident breast cancers, is the only breast cancer (BC) subtype that lacks targeted treatments. Using clinical assays, TNBC is human epidermal growth factor receptor 2 (HER2) negative and has <1% expression of estrogen receptor...
Triple negative breast cancer is more often responsive to chemotherapy than hormone receptor positive (ER+/PR+) breast cancer. On the other hand, long-term hormonal treatments (tamoxifen, aromatase inhibitors) used for ER+ subtypes are not effective for triple negative breast cancer since estrogen ...
Triple-negative Breast Cancer: Adjuvant Capecitabine May Improve OutcomesJonathan GoodmanMPhilOncology Editor
What set the alarm bells ringing is that Kashmir has the second highest prevalence of triple-negative breast cancer, which is around 33 to 35%
The development of immunotherapy agents has revolutionized the field of oncology. The only FDA-approved immunotherapeutic approach in breast cancer consists of immune checkpoint inhibitors, yet several novel immune-modulatory strategies are being activel
Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and progesterone receptor expression and lacks HER2 overexpression or gene amplification. It accounts for 10–15% of incident breast cancers and carries the worst prognosis. TN
There are comments on PubPeer for publication: Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape (2021)